Scarica l'app Stockscreener
53.79
7.72%
3.9799
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$49.81
Aprire:
$50.24
Volume 24 ore:
21.74M
Relative Volume:
1.89
Capitalizzazione di mercato:
$20.99B
Reddito:
$3.14B
Utile/perdita netta:
$-3.36B
Rapporto P/E:
-6.1615
EPS:
-8.73
Flusso di cassa netto:
$-4.03B
1 W Prestazione:
+36.32%
1M Prestazione:
+53.74%
6M Prestazione:
+63.93%
1 anno Prestazione:
+39.37%
Intervallo 1D:
$50.05
$55.20
Intervallo di 1 settimana:
$40.55
$55.20
Portata 52W:
$22.28
$55.20
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Confronta MRNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
53.73 | 19.46B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.38 | 117.00B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
756.39 | 78.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
820.72 | 50.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
368.11 | 48.28B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.92 | 37.81B | 4.98B | 69.59M | 525.67M | 0.5197 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-12 | Iniziato | Jefferies | Hold |
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
Moderna (MRNA) Stock Surge Boosts ETFs with High Exposure - GuruFocus
Moderna (MRNA) Surges Over 20% This Week, Hits 52-Week High - GuruFocus
Moderna (MRNA) CEO Cites U.S. Vaccine Opposition as Barrier to N - GuruFocus
Moderna curbing investments in vaccine trials due to US backlash, CEO tells Bloomberg TV - Reuters
Moderna’s rally ripples through biotech and health care ETFs - Seeking Alpha
Moderna (MRNA) Surges Amid Market Gains - GuruFocus
Moderna’s 2026 Pivot: From Pandemic Pioneer to Oncology Powerhouse - FinancialContent
Moderna Stock Explodes To New 52-Week High: What's Driving The Action? - Benzinga
Moderna shares soar through the week, momentum data points toward caution (MRNA:NASDAQ) - Seeking Alpha
Moderna Is Curbing Investment in Vaccine Trials Due to US Backlash - Bloomberg.com
Moderna extends YTD rally to hit 52-week high (MRNA:NASDAQ) - Seeking Alpha
Moderna Stock Soars. Why a Cancer Vaccine Study Has Sparked a Rally. - Barron's
Buy or Sell Moderna Stock At $50? - Trefis
Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Rise As BEA Pegs Q3 GDP At 4.4%— Microsoft, Moderna, Intel In Focus (UPDATED) - Benzinga
These Stocks Are Today’s Movers: Moderna, Intel, GE Aerospace, Abbott, Micron, Mobileye, Venture Global, and More - Barron's
Moderna (MRNA) Touches 52-Week High on Strong Clinical Results - Finviz
Moderna (MRNA) Stock Climbs 16% on Melanoma Vaccine Breakthrough - Blockonomi
Moderna, Intel, GameStop, Micron, Venture Global, and More Stock Market Movers - Barron's
Moderna Stock Is Surging. Why a Cancer Vaccine Study Has Sparked a Rally. - Barron's
Moderna extends rally after drug-trial results, and other early market movers - MarketWatch
Stock Market Today: S&P 500, Dow Jones Futures Rise As Trump Scales Down EU Tariff Threats—Microsoft, Moderna, Intel In Focus - Benzinga
Trending tickers: AMD, Intel, Moderna, Associated British Foods and Young & Co's Brewery - Yahoo Finance UK
Moderna (MRNA) Stock: Melanoma Vaccine Data Pushes Shares to 52-Week High - CoinCentral
Moderna Inc.: From Pandemic Breakout Star to Platform Powerhouse - AD HOC NEWS
Moderna Stock Soars 16%, Hits 52-Week High as "mRNA 2.0" Cancer Vaccine Data Stuns Markets - FXLeaders
Analysts Favor Novavax Over Moderna After $30M Pfizer Licensing Deal - Intellectia AI
Growth Recap: How volatile is Moderna Inc stockJuly 2025 Decliners & High Accuracy Investment Entry Signals - baoquankhu1.vn
Intel, Moderna, TMC, Microsoft And Lucid: Why These 5 Stocks Are On Investors' Radars TodayIntel (NASDAQ:INTC) - Benzinga
Moderna (MRNA) Shares Surge 15.84% on Positive Skin Cancer Vaccine Trial Results with Merck - Intellectia AI
Why Moderna Stock Surged Today - Yahoo Finance
MRNA Vs NVAX: Which Vaccine Stock Is Wall Street More Bullish On Right Now? - Stocktwits
Moderna’s Groundbreaking Combo Drug Trials with Merck - timothysykes.com
U.S. Markets Rose Wednesday; Moderna Led Increases - Barron's
Moderna and Merck pop on cancer vaccine, Lucid-Rockwell partnership - Yahoo Finance
Moderna Stock Skyrockets To 52-Week High: What's Behind The Surge? - Benzinga
Moderna (NASDAQ:MRNA) Sets New 1-Year HighWhat's Next? - MarketBeat
Moderna (MRNA) Shares Skyrocket, What You Need To Know - Finviz
Promising Biotech Stocks To ConsiderJanuary 21st - MarketBeat
Moderna’s Strategic Growth Propels Stock Upwards - StocksToTrade
Why Is Moderna (MRNA) Stock Up Today: Merck Partnered Vaccine Cuts Recurrence Risk - Tokenist
Moderna stock hits 52-week high at $45.44 By Investing.com - Investing.com Australia
Moderna stock hits 52-week high at $45.44 - Investing.com
The Truth About Moderna Inc: Is MRNA Still a Pandemic One-Hit Wonder or a Silent Beast? - AD HOC NEWS
Sumitomo Mitsui Trust Group Inc. Reduces Position in Moderna, Inc. $MRNA - MarketBeat
Moderna Cancer Data Sparks Questions On Oncology Pivot And Stock Valuation - simplywall.st
BofA Raises Moderna Price Target to $27, Maintains Underperform Rating - Intellectia AI
Moderna Stock Still Worth 37% Less After Cancer Vaccine Data? BofA’s New Price Target Keeps Retail Traders Cautious - Stocktwits
Moderna (MRNA) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance
Merck/Moderna Intismeran Data Show Continued Efficacy In Melanoma - Citeline News & Insights
Moderna, Merck's skin cancer vaccine shows sustained benefit in five-year follow-up - Reuters
Moderna Pops 17%—Is There Life in MRNA, Down 90% from COVID High? - MarketBeat
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Moderna Inc Azioni (MRNA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| AFEYAN NOUBAR | Director |
Dec 11 '25 |
Sale |
29.48 |
23,853 |
703,306 |
3,924 |
| Bancel Stephane | Chief Executive Officer |
Dec 11 '25 |
Option Exercise |
10.90 |
688,073 |
7,499,996 |
6,181,970 |
0.85%
0.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):